Cancer Network (2/8, Fowler) reports researchers examined “the prevalence, risk factors, and prognostic value of chemotherapy-associated venous thromboembolism (VTE) in patients with ovarian cancer” and “found a pooled prevalence of 9% for this group of patients.” In addition, “the data also found substantial risk factors for chemotherapy-related VTE, potentially assisting future efforts to target preventative measures in patients with this disease.” The findings were published in the World Journal of Surgical Oncology.
